Alnylam PharmaceuticalsLTS:0HD2 67 PB Ratio is 38.73 as of Jul. 04, 2026, which is 232% above its 10-year median of 11.68. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $517.19 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Alnylam Pharmaceuticals ranks worse than 96.66% on this metric.
The historical rank and industry rank for Alnylam Pharmaceuticals's PB Ratio or its related term are showing as below:
LTS:0HD2'
s PB Ratio Range Over the Past 10 Years
Min: 2.85 Med: 11.68 Max: 1179
Current: 38.81
During the past 13 years, Alnylam Pharmaceuticals's highest PB Ratio was 1179.00. The lowest was 2.85. And the median was 11.68.
LTS:0HD2's PB Ratio is ranked worse than 96.66% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs LTS:0HD2: 38.81
During the past 12 months, Alnylam Pharmaceuticals's average Book Value Per Share Growth Rate was 809.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Alnylam Pharmaceuticals was 79.90% per year. The lowest was -52.70% per year. And the median was -0.20% per year.
Back to Basics: PB Ratio
Alnylam Pharmaceuticals (LTS:0HD2) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alnylam Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alnylam Pharmaceuticals (LTS:0HD2) has a PB Ratio of 38.73 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alnylam Pharmaceuticals and its competitors. This is 232% above median its historical median of 11.68. Over the past decade, Alnylam Pharmaceuticals' PB Ratio has ranged from 2.85 to 1,179.00. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #1187 out of 1228 companies in the Biotechnology industry, placing it in the top 96.7%.
Is Alnylam Pharmaceuticals' PB Ratio too high?
Alnylam Pharmaceuticals' current PB Ratio of 38.73 is 232% above median its 10-year median of 11.68. Over the past 10 years, this metric has ranged from a low of 2.85 to a high of 1,179.00. The Biotechnology industry median PB Ratio is 2.97. Alnylam Pharmaceuticals' value of 38.73 is 1204% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #1187 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' PB Ratio compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #1187 out of 1228 companies for PB Ratio. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.97. Alnylam Pharmaceuticals' value of 38.73 is 1204% above this benchmark. Historically, Alnylam Pharmaceuticals' own PB Ratio has ranged from 2.85 to 1,179.00 over the past decade. While the company's 10-year median is 11.68 vs. the industry median of 2.97, Alnylam Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current PB Ratio of 38.73 is 1204% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current PB Ratio is 38.73, which is 232% above median its own 10-year median of 11.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $517.19, compared to a current price of $312.13 — trading 39.6% below its estimated fair value. The current PB Ratio is 38.73, which is 232% above median its 10-year median of 11.68 and 1204% above the Biotechnology industry median of 2.97. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current PB Ratio is 38.73 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $312.13 is trading 39.6% below its estimated GF Value™ of $517.19.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
PB Ratio: 38.73 (232% above median its 10-year median of 11.68)
GF Value™: $517.19 vs. price of $312.13 (39.6% below fair value)
Industry Position: 1204% above the Biotechnology median (#1187 of 1228)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
